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WATER SOLUBLE AMINE ESTERS OF
TESTOSTERONE FOR INTRANASAL
ADMINISTRATION

promptly by the liver so that insigni?cant amounts reach the

systemic circulation; When injected parenterally, testoster
one is rapidly absorbed from the injection vehicle and
rapidly degraded. As a consequence, effective androgen
therapy requires either the administration of testosterone in
a sloWly absorbed dosage form or the administration of
modi?ed analogs of testosterone dissolved in oil vehicle.
Such chemical modi?cations represent attempts to retard the

FIELD OF THE INVENTION

This invention relates generally to novel Water-soluble
prodrugs of testosterone suitable for intranasal administra
tion to mammals, including humans, in need of testosterone

rate of metabolism of testosterone, so as to sustain effective

replacement therapy. More speci?cally, this invention relates

blood levels, due to sloW conversion of the ester. Three types
of modi?cation of the molecule have received Widespread

to a Water-soluble form of testosterone Which is suitable for
intranasal administration. This invention also relates to a

clinical application, namely, esteri?cation of the 176
hydroXyl group, alkylation at the 17a position, and modi

testosterone replacement therapy Which comprises intrana
sal administration of one or more of the Water-soluble forms

of testosterone of the present invention.
15

BACKGROUND

Testosterone (17B-hydroXyandrost-4-en-3-one) and its
metabolite, dihydrotestosterone, are the primary endogenous

Esteri?cation serves to decrease the polarity of the molecule.
Consequently, the steroid is more soluble in the fat vehicles

androgenic hormones (androgens). Endogenous androgens
are responsible for the normal groWth and development of
the male seX organs and for development and maintenance
of secondary seX characteristics. These effects include the

groWth and maturation of the prostate, seminal vesicles,
penis, and scrotum; the development of male hair
distribution, such as facial, pubic, chest, and aXillary hair;
laryngeal enlargement, vocal cord thickening, alterations in
body musculature, and fat distribution.
These compounds also cause retention of nitrogen,

?cation of the ring structure, particularly substitutions at the
2, 9, and 11 positions. Most agents actually contain combi
nations of ring structure alterations and either 170.
alkylation or esteri?cation of the 17[3-hydroXyl moiety.

25

used for injection, and release of the steroid into the circu
lation is sloWed. Most esters must be injected parenterally,
a route of administration Which, because it is painful and
inconvenient, is dif?cult for patients to self-administer in a
chronic therapeutic regimen. Furthermore, the more carbon
molecules in the acid esteri?ed, the more prolonged is the
action of the modi?ed compound. Esters such as testoster

one cypionate (testosterone cyclopentanepropionate) and
testosterone enanthate (testosterone heptanoate) are typi

sodium, potassium phosphorous, and decreased urinary

cally injected every 1 to 3 Weeks. These esters are hydro
lyZed before the hormones act; thus the effectiveness of

excretion of calcium. Androgens have also been reported to
increase protein anabolism and decrease protein catabolism.
Androgens are responsible for the groWth spurt of adoles

level With time folloWing administration.

cence and for the eventual termination of linear groWth

as methyl-testosterone and methandrostenolone) is due to

brought about by fusion of the epiphyseal groWth centers. In
children, eXogenous androgens accelerate linear groWth rate

therapy must be monitored by assaying plasma testosterone

The oral effectiveness of 17ot-alkylated androgens (such
35

but may cause a disproportionate advancement in bone

the liver and reach the systemic circulation. For this reason,

maturation. Androgens have been reported to stimulate the

17ot-methyl or -ethyl substitution is a common feature of

production of red blood cells by enhancing the production of

most orally active androgens. Unfortunately, all 170.
alkylated steroids can produce cholestatic hepatitis and

erythropoietin.
The range of plasma testosterone levels in normal adult
men is from 10 to 35 nmol/L (3 to 10 ng/ml). There are
clinical conditions in Which testosterone levels are decreased

jaundice, and other liver function abnormalities such as

elevation of plasma alkaline phosphatase and conjugated
bilirubin, even at loW doses. The most serious complications

from normal levels. Disorders associated With hypotestoster

onemia include primary hypogonadism (congenital or
acquired), testicular failure due to cryptorchidism, bilateral

sloWer hepatic catabolism than occurs With testosterone

itself, so that the alkylated derivatives escape degradation by

of 17ot-alkylated androgen therapy are the development of
45

peliosis hepatitis (blood-?lled cysts in the liver) and
hepatoma. While patients With preexisting liver disease are
particularly susceptible to these serious side effects, they are

torsion, Cushing’s syndrome, congenital adrenal
hyperplasia, hyperprolactinemia, Kinefelter’s syndrome,
orchitis, sickle cell anemia, Hodgkin’s disease, amyloidosis,

frequently seen even in patients Without a history of clinical
liver disease. 17ot-Alkylated drugs also cause an increase in

cirrhosis of the liver, and chronic renal failure. Decreases in
plasma testosterone may also accompany surgery,

Finally, the relatively infrequent administration of these

chemotherapy, spinal cord injury, myocardial infarction,

drugs results in a Wide range in postadministration plasma

severe burns, and toXic damage from eXposure to alcohol or
heavy metals. In any or all of these conditions it may be

testosterone values.

desirable for the patient to undergo testosterone replacement

therapy.

a variety of plasma proteins that are synthesiZed in the liver.

55

Testosterone also antagoniZes a number of the effects of

estrogens, and sometimes is employed clinically for this
purpose. This is especially important in the suppression of

Although testosterone is knoWn to be absorbed from the
nasal cavity, its insolubility in Water makes its intranasal
administration impractical (see, e.g., Hussain et al., J.
Pharm. Sci. 73: 1300—1301, 1984). Transdermal prepara
tions of testosterone in Which a testosterone-loaded patch is

applied each day have recently become available
(Testoderm®, AlZa Corporation, Palo Alto, Calif.). This

metastatic carcinoma of the breasts. Testosterone and its

esters (e.g., testosterone propionate) and derivatives (e.g.,
methyltestosterone) also promotes retention of calcium, and

therapy avoids the Wide sWings in serum testosterone values
that occur betWeen injections of testosterone esters, and

may be useful in treatment of osteoporosis.
HoWever, oral administration of testosterone itself is
generally ineffective as a means for increasing circulating

transdermal patch Will not produce adequate serum testoster
one concentration if applied to nongenital skin. In order to

alloWs for self-administration by the patient. HoWever, the
65

testosterone levels. When testosterone per se is administered

deliver an effective amount of testosterone into the

by mouth, it is absorbed into the portal blood and degraded

bloodstream, the transdermal patch must be applied directly

US 6,423,701 B1
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to a shaved area of the scrotum, Where it must be Worn for

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS OF THE
INVENTION

22—24 hours per day. Furthermore, any testosterone remain
ing on the skin following removal of the patch may be
transferred to the patient’s sexual partner. Finally, the trans

The present invention is a neW Water-soluble testosterone

dermal patch suffers from the disadvantage of being

extremely expensive.
In vieW of the foregoing, it is apparent that there exists a
need in the art for an improved method of delivery of
testosterone for use in testosterone replacement therapy.
Surprisingly, the present inventor has found that intrana

10

sal administration of a novel form of testosterone offers

signi?cant advantages over the prior art. Those advantages
include rapid absorption, and easy and reliable self
administration.
15

SUMMARY OF THE INVENTION

prodrug suitable for intranasal administration. The intranasal
administration of testosterone prodrugs offers signi?cant
clinical advantages over the prior art. Furthermore, the
present invention provides a safe, effective and convenient
treatment for testosterone de?ciency by intranasally admin
istering the Water-soluble testosterone prodrugs of the
present invention. This avoids the problems associated With
the injectable and transdermal dosage forms of testosterone.
The present inventor has found that intranasal adminis
tration of the Water-soluble testosterone prodrugs of the
present invention may be advantageously used in a regimen
of testosterone replacement therapy. Intranasal administra
tion of these compounds is as effective as intravenous

Accordingly, since parenteral administration of testoster
one analogs results in Wide sWings in plasma testosterone
levels, and since chronic self-administration of injectable
dosage forms is impractical, and since transdermal dosage

administration, hoWever, intranasal administration offers the
signi?cant advantage that it can be conveniently and pain

lessly self-administered by the patient.
Preferred testosterone prodrugs Will have the folloWing

forms are expensive and inconvenient, it is an object of the
present invention to provide a Water-soluble form of test

chemical structure:

osterone suitable for intranasal administration for use in

testosterone replacement therapy.

OR

25

It is a further aspect of this invention to provide a
Water-soluble form of testosterone suitable for intranasal
administration Which is equal to or superior to prior art

CH3

injectable and transdermal dosage forms in many respects,
including effectiveness, but Which avoids many of the prob
lems associated With injectable and transdermal dosage
forms, While offering superior ease of administration.

0

It is yet a further aspect of this invention to provide a

Wherein R has the folloWing chemical structure:

method of testosterone replacement therapy by intranasally
administering the Water-soluble form of testosterone of the
present invention to a mammalian organism, especially a

35

human, in need of testosterone replacement therapy.
It is a still further aspect of this invention to provide a
method for administering testosterone Which is equal to or

superior to administration of injectable dosage forms in
many respects, including effectiveness, but Which avoids
many of the problems associated With injectable dosage
forms, While offering superior ease of administration.
A further aspect of this invention is to provide a pharma

ceutical composition suitable for intranasal administration,
for use in testosterone replacement therapy. Accordingly, the
composition of the present invention comprises an effective

and R1 and R2 are loWer alkyl, more preferably straight
chain alkyl, most preferably methyl, ethyl, or propyl. The
most preferred Water-soluble testosterone prodrug is

testosteronyl, N,N-dimethyl amine glyconate (TSDG). Phar
45

limited to, salts of organic carboxylic acids, such as acetic,
lactic, tartaric, malic, isothionic, lactobionic and succinic
acids; organic sulfonic acids, such as methanesulfonic,
ethanesulfonic, benZenesulfonic and p-tolylsulfonic acids,
and inorganic acids, such as hydrochloric, sulfuric, phos
phoric and sulfamic acids.

amount of the Water-soluble form of testosterone of the
present invention achieve a desired testosterone level, and a

pharmaceutically acceptable carrier therefor.
With the foregoing and other objects, advantages and
features of the invention that Will become hereinafter
apparent, the nature of the invention may be more clearly

understood by reference to the folloWing detailed descrip
tion of the preferred embodiments of the invention and to the

55

appended claims.
FIG. 1: Time course of plasma levels of testosteronyl,

N,N-dimethyl amine glyconate (TSDG) and testosterone
(TS) folloWing intranasal administration of TSDG (25.0
mg.kg) in rats.
FIG. 2: Time course of conversion of TSDG to TS in liver

FIG. 3: Time course plot illustrating stability of TSDG in

H20.

A further aspect of this invention is a pharmaceutical
composition of matter for intranasal testosterone replace
ment therapy that comprises the Water-soluble testosterone
prodrugs as described above, mixtures of Water-soluble

testosterone prodrugs, and/or pharmaceutical salts thereof,
and pharmaceutically acceptable carriers therefor. Such
compositions are prepared in accordance With accepted
pharmaceutical procedures, for example, as described in
Remington ’s Pharmaceutical Sciences, seventeenth edition,
ed. Alfonso R. Gennaro, Mack Publishing Company, Easton,

BRIEF DESCRIPTION OF THE DRAWINGS

homogenate.

maceutically acceptable salts of the compounds of the
present invention are also preferred.
Pharmaceutically acceptable salts include, but are not

Pa., Eighteenth edition (1990).
65

For therapeutic use in a regimen of testosterone replace
ment therapy, a Water-soluble testosterone prodrug, or its
salt, can be conveniently administered in the form of a nasal

US 6,423,701 B1
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pharmaceutical composition containing a Water-soluble tes
tosterone prodrug, or its salt, and a pharmaceutically accept

comprise at least one active ingredient, as de?ned above,
together With one or more acceptable carriers thereof and

able carrier therefor. Suitable carriers for intranasal admin

optionally other therapeutic agents.

istration are Well knoWn to those skilled in the art and vary

The above method may be practiced by administration of

With the desired form and mode of administration of the

the compounds by themselves or in a combination With other

active ingredients in a pharmaceutical composition. Other

pharmaceutical composition. Typically, the carrier may be a

liquid, suspension, semi-solid, gel, or vaporiZable carrier, or
combinations thereof. In a preferred embodiment, the carrier
is a pharmaceutically acceptable aqueous carrier.
The compound of the present invention or its salt may be
formulated together With the carrier into any desired unit
dosage form. Unit dosage forms such as solutions,
suspensions, and Water-miscible semisolids are particularly

10

preferred.
Each carrier must be “acceptable” in the sense of being

15

compatible With the other ingredients in the formulation and
not injurious to the patient. The carrier must be biologically
acceptable and inert. To prepare formulations suitable for
intranasal administration, solutions and suspensions are ster
iliZed and are preferably isotonic to blood.

The method of the present invention may be used in con
20

failure due to cryptorchidism, bilateral torsion, Cushing’s

carriers or ?nely divided semi-solid carriers or both. Various

unit dose and multidose containers, e.g., sealed ampules and
30

In addition to the ingredients particularly mentioned
above, the formulations of this invention may also include
other agents conventional in the art for this type of intranasal

syndrome, congenital adrenal hyperplasia,
hyperprolactinemia, Klinefelter’s syndrome, orchitis, sickle
cell anemia, Hodgkin’s disease, amyloidosis, cirrhosis of the
liver, and chronic renal failure. Decreases in plasma test
osterone may also accompany surgery, chemotherapy, spinal
cord injury, myocardial infarction, severe burns, and toxic
damage from exposure to alcohol or heavy metals. HoWever,
the preceding conditions are not intended to be limiting, and

pharmaceutical formulation.
35

increasing plasma levels of testosterone in a mammal, e.g.,
a human, by treating the mammal With an effective amount
of a Water-soluble testosterone prodrug. For purposes of the

Weight, and species of the patient, the general health of the
patient, the severity of the symptoms, the potency of the
Water-soluble testosterone prodrug, Whether the composition

tioner.
The present invention may be used to increase plasma

testosterone levels in patients suffering from, for instance,
primary hypogonadism (congenital or acquired), testicular

encompass one or more accessory ingredients. In general, 25

present invention, the patient can be any mammal in need of
increased plasma levels of testosterone.
The dosage of the Water-soluble testosterone prodrug or
mixture thereof administered to a patient Will vary depend
ing on several factors, including, but not limited to, the age,

adjusted by the practitioner, by preferably initially loWering
junction With other therapies as determined by the practi

the formulations are prepared by uniformly and intimately
bringing into association the active ingredient With liquid

The present invention is also directed to a method of

The compounds utiliZed in combination therapy may be
administered simultaneously, in either separate or combined
formulations, or at different times than the present
compounds, e.g., sequentially, such that a combined effect is
achieved. The amounts and regime of administration Will be

their standard doses and then titrating the results obtained.

The formulations may conveniently be presented in unit
dosage form and may be prepared by any method knoWn in
the art. Such methods include the step of bringing the active
ingredient into association With the carrier Which itself may

vials, may be used, as is Well knoWn in the art.

therapeutic agents suitable for use herein are any compatible
drugs that are effective by the same or other mechanisms for
the intended purpose, or drugs that are complementary to
those of the claimed invention.

40

treatment of any condition Which requires increased plasma
testosterone levels is intended to be encompassed by the
present invention.
Having noW generally described this invention, the same
Will be better understood by reference to certain speci?c
examples, Which are included herein for purposes of illus
tration only and are not intended to be limiting of the
invention or any embodiment thereof, unless so speci?ed.
EXAMPLE
Intranasal Administration of TSDG
The nasal absorption of the Water soluble testosterone
prodrug TSDG Was studied using an in vivo experimental

45

technique previously described by Huang et al.

(J.Pharmaceut. Sci, 74: 608—611, 1985).

is being administered alone or in combination With other
agents, the incidence of side effects and the like.
For instance, the desired dose may be administered as 1

Male Sprague-DaWley rats Weighing 250—275 gm Were
used. Animals Were fasted overnight before the experiment,
but Water Was given ad libitum. All surgical procedures Were

to 6 or more subdoses administered at appropriate intervals 50

performed under sodium pentobarbital anesthesia (40 mg/kg

throughout the day. The compounds may be administered

i.p.). An incision Was made in the neck, and the trachea Was
cannulated With a polyethylene tube. A closed tube Was

repeatedly over a period of months or years, or it may be

sloWly and constantly administered to the patient. Higher

inserted through the esophagus to the posterior part of the

and loWer doses may also be administered.

nasal cavity. The nasopalatine passage Was closed With an

The daily dose may be adjusted taking into account, for
example, the above-identi?ed variety of parameters.
Typically, the present compositions may be administered

55

Blood samples Were collected from a cannula inserted

intranasally in an amount of about 0.001 to 100.0 mg/kg

body Weight/day. HoWever, other amounts may also be
administered.

60

To achieve good plasma concentrations, the active com

pounds may be administered, for instance, by intranasal
administration of an approximate 0.1 to 1M solution of the

active ingredient, optionally in saline.
While it is possible for the active ingredient to be admin
istered alone, it is preferably administered in a pharmaceu
tical formulation. The formulations of the present invention

adhesive agent to prevent drainage of the drug from the nasal
cavity to the mouth.
into the femoral artery. For intravenous administration, the
jugular vein Was cannulated for administering the dose.
Preparation of the Solutions
Drug solutions at 25 and 50 mg/kg/0.2 ml equimolar
doses of TSDG Were freshly prepared by using 0.05M
phosphate buffer at pH 6.0. For nasal administration, aque
ous solutions of TSDG and testosterone Were administered

65

through the nostril using a microsyringe. For intravenous
administration, the same dose of the drug Was injected

through the jugular vein.

US 6,423,701 B1
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4. An intranasal pharmaceutical composition comprising

Sample Collection after Nasal and Intravenous Administra
tions

Blood samples Were collected at 0, 5, 10, 20, 30, 40, 60,
90, 120, 150, and 180 minutes. After immediate centrifuga
tion (3000><g for 3 min), the plasma Was separated. The

a testosterone analog having the folloWing chemical struc
ture:
5

OR

CH3

animal Was sacri?ced after the last sample Was obtained, and

the samples Were then analyZed by HPLC, using the method
of Hsyu et al. (Pharm. Res. 11:156—159, 1994). Brie?y,

CH3

plasma concentrations of testosterone free base Were deter

mined via a HPLC protocol Which included solid-phase
extraction, separation on a reverse-phase cyano column, and

10

UV detection at 305 nm.

Results
Table 1 shoWs area under the curve (AUC; pg’khr/ml) after
intravenous and intranasal administration of TSDG and

wherein R is:
15

testosterone (TS) at doses of 50 mg/kg and 25 mg/kg.
TABLE 1
DOSE

50 mg/kg

ROUTE
AUC for TSDG
AUC for TS

0

25 mg/kg

R2

20

Intravenous

Intranasal

Intravenous

Intranasal

2.83
3.78

2.66
3.49

1.65
1.77

1.63
1.83

and Wherein R1 and R2 are loWer alkyl, and a pharmaceu

tically acceptable carrier therefor.
5. A pharmaceutical composition comprising a testoster
one analog according to claim 2 and a pharmaceutically

acceptable carrier therefor.
6. A pharmaceutical composition comprising a testoster

The ?gure shoWs plasma TSDG and TS levels after
intranasal administration at a dose of 25.0 mg/kg. Absorp
tion of TSDG Was rapid; plasma levels at all time points
Were comparable to those following intravenous adminis
tration.

one analog according to claim 3 and a pharmaceutically
30

TSDG Was also found to convert rapidly to TS in human

acceptable carrier therefor.
7. A method for increasing plasma testosterone levels
comprising intranasally administering to a mammal in need
of such treatment an effective amount of a testosterone

liver homogenate as shoWn in FIG. 2. On the other hand,
analog having the folloWing structure:
TSDG Was found to be very stable in Water, as shoWn in
FIG. 3.
OR
While the invention has been described herein by refer 35
CH3
ences to various speci?c materials, procedures, and
examples, it is understood that the invention is not restricted
CH3

to the particular materials, combinations of materials, and
procedures selected for that purpose. Numerous variations
of such details can be implied and Will be appreciated by

40

those skilled in the art.
What is claimed is:

1. AWater-soluble testosterone analog having the folloW
ing chemical structure:

wherein R is:
45

R1

OR

CH3
CH3
50

and Wherein R1 and R2 are loWer alkyl.
8. The method of claim 7, Wherein the testosterone analog
is administered at a dose of 0.1 to 1.0 mg/kg body Weight/

0

day.
55

Wherein R is:

9. A method for increasing plasma testosterone levels
comprising intranasally administering to a patient in need of
such treatment an effective amount of a testosterone analog

R1

/
—C—CH2—N
0

R2

and R1 and R2 are loWer alkyl.
2. Atestosterone analog according to claim 1, Wherein R1
and R2 are straight-chain alkyl.
3. Atestosterone analog according to claim 1, Wherein R1
and R2 are methyl, ethyl, or propyl.

aO

according to claim 2.
10. The method of claim 9, Wherein the testosterone
analog is administered at a dose of 0.1 to 1.0 mg/kg body

Weight/day.
11. A method for increasing plasma testosterone levels
comprising intranasally administering to a patient in need of
such treatment an effective amount of a testosterone analog

according to claim 3.
12. The method of claim 11, Wherein the testosterone
analog is administered at a dose of 0.1 to 1.0 mg/kg body

Weight/day.

US 6,423,701 B1
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13. A method for increasing plasma testosterone levels
comprising intranasally administering to a patient in need of

15. A method for increasing plasma testosterone levels
comprising intranasally administering to a patient in need of

such treatment an effective amount of the pharmaceutical

such treatment an effective amount of the pharmaceutical

composition of claim 4.
14. A method for increasing plasma testosterone levels
comprising intranasally administering to a patient in need of

composition of claim 6.

such treatment an effective amount of the pharmaceutical

composition of claim 5.

